What is a stock summary page? Click here for an overview.
Business Description
Trinity Biotech PLC
NAICS : 339112
SIC : 3845
ISIN : US8964383066
Share Class Description:
TRIB: ADRDescription
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.03 | |||||
| Equity-to-Asset | -0.27 | |||||
| Debt-to-Equity | -3.56 | |||||
| Debt-to-EBITDA | -11.19 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.32 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -36 | |||||
| 3-Year Book Growth Rate | -80.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 47.88 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.82 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.54 | |||||
| 9-Day RSI | 50.18 | |||||
| 14-Day RSI | 46.54 | |||||
| 3-1 Month Momentum % | -0.89 | |||||
| 6-1 Month Momentum % | -34.39 | |||||
| 12-1 Month Momentum % | -61.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.64 | |||||
| Quick Ratio | 0.87 | |||||
| Cash Ratio | 0.1 | |||||
| Days Inventory | 207.91 | |||||
| Days Sales Outstanding | 100.98 | |||||
| Days Payable | 160.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -22.4 | |||||
| Shareholder Yield % | -76.23 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.74 | |||||
| Operating Margin % | -17.62 | |||||
| Net Margin % | -34.39 | |||||
| FCF Margin % | -26.25 | |||||
| ROA % | -25.1 | |||||
| ROIC % | -18.02 | |||||
| 3-Year ROIIC % | 73.89 | |||||
| ROC (Joel Greenblatt) % | -45.59 | |||||
| ROCE % | -17.09 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.13 | |||||
| EV-to-EBIT | -10.74 | |||||
| EV-to-EBITDA | -13.18 | |||||
| EV-to-Revenue | 1.87 | |||||
| EV-to-Forward-Revenue | 1.6 | |||||
| EV-to-FCF | -7.05 | |||||
| Price-to-GF-Value | 0.27 | |||||
| Price-to-Median-PS-Value | 0.16 | |||||
| Earnings Yield (Greenblatt) % | -9.31 | |||||
| FCF Yield % | -84.89 | |||||
| Forward Rate of Return (Yacktman) % | -306.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TRIB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Trinity Biotech PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 59.127 | ||
| EPS (TTM) ($) | -2.28 | ||
| Beta | 0.68 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 111.26 | ||
| 14-Day RSI | 46.54 | ||
| 14-Day ATR ($) | 0.06405 | ||
| 20-Day SMA ($) | 0.714469 | ||
| 12-1 Month Momentum % | -61.32 | ||
| 52-Week Range ($) | 0.6251 - 3.55 | ||
| Shares Outstanding (Mil) | 27.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Trinity Biotech PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Trinity Biotech PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Trinity Biotech PLC Frequently Asked Questions
What is Trinity Biotech PLC(TRIB)'s stock price today?
The current price of TRIB is $0.66. The 52 week high of TRIB is $3.55 and 52 week low is $0.63.
When is next earnings date of Trinity Biotech PLC(TRIB)?
The next earnings date of Trinity Biotech PLC(TRIB) is 2025-04-04 Est..
Does Trinity Biotech PLC(TRIB) pay dividends? If so, how much?
Trinity Biotech PLC(TRIB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers